Patents by Inventor Sachin Mittal

Sachin Mittal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230009897
    Abstract: Some embodiments may facilitate software development and operations for an enterprise. A communication input port may receive information associated with a software continuous integration/deployment pipeline of the enterprise. An intelligent software agent platform, coupled to the communication input port, may listen for a trigger indication from the software continuous integration/deployment pipeline. Responsive to the trigger indication, the intelligent software agent platform may apply system configuration information and rule layer information to extract software log data and apply a machine learning model to the extracted software log data to generate a pipeline health check analysis report. The pipeline health check analysis report may include, for example, an automatically generated prediction associated with future operation of the software continuous integration/deployment pipeline.
    Type: Application
    Filed: September 20, 2022
    Publication date: January 12, 2023
    Inventors: Renoi Thomas, Satish Venugopal, Sachin Mittal, Sandeep Kumar Yaramchitti
  • Patent number: 11487948
    Abstract: An autonomous automated intent mining system extracts intents from stored conversations in a text-based chat corpus for use in an AI-driven dialog system. The intent mining system includes an intelligent pre-processor for extracting the conversation data from a computer memory and operating on the conversation data to identify relevant utterances. The system additionally includes a representation processor for operating on the identified relevant utterances to create a numerical representation. The system also includes a clustering processor for generating clusters of utterances and classifying each of the identified relevant utterances into a cluster based on the numerical representation of each utterance. Each generated cluster represents a unique intent for use in the AI-driven dialog system.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: November 1, 2022
    Assignee: Conduent Business Services, LLC
    Inventors: Simarjot Kaur, Sachin Mittal, Sandya Srivilliputtur Mannarswamy
  • Patent number: 11481209
    Abstract: Some embodiments may facilitate software development and operations for an enterprise. A communication input port may receive information associated with a software continuous integration/deployment pipeline of the enterprise. An intelligent software agent platform, coupled to the communication input port, may listen for a trigger indication from the software continuous integration/deployment pipeline. Responsive to the trigger indication, the intelligent software agent platform may apply system configuration information and rule layer information to extract software log data and apply a machine learning model to the extracted software log data to generate a pipeline health check analysis report. The pipeline health check analysis report may include, for example, an automatically generated prediction associated with future operation of the software continuous integration/deployment pipeline.
    Type: Grant
    Filed: January 21, 2021
    Date of Patent: October 25, 2022
    Assignee: HARTFORD FIRE INSURANCE COMPANY
    Inventors: Renoi Thomas, Satish Venugopal, Sachin Mittal, Sandeep Kumar Yaramchitti
  • Patent number: 11471512
    Abstract: Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 18, 2022
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Himanshu Bhattacharjee, Suzanne M. D'Addio, Sachin Lohani, Sachin Mittal, Sergei Y. Pechenov, Daniel Hong Yin
  • Publication number: 20220306619
    Abstract: The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: March 15, 2022
    Publication date: September 29, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sachin Mittal, Jason W. Skudlarek, Izzat T. Raheem
  • Publication number: 20220175811
    Abstract: The invention relates to stable formulations of cyclic dinucleotide STING agonist compounds or pharmaceutically acceptable salts thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intratumoral or subcutaneous administration.
    Type: Application
    Filed: March 24, 2020
    Publication date: June 9, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Margaret Brunell, Erin N. Guidry, Yash Kapoor, Eric A. Kemp, Ellen C. Minnihan, Sachin Mittal, Elizabeth Pierson, Mikhail Reibarkh, Tammy W. Shen, Erika R. Walsh, Paul L. Walsh
  • Publication number: 20220089738
    Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof and a PH20 variant or fragment thereof. The invention further provides methods for treating various cancers with formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by subcutaneous administration.
    Type: Application
    Filed: September 23, 2021
    Publication date: March 24, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Yogita Krishnamachari, Sachin Mittal, Sahil S. Sangani, William P. Forrest, JR., Yongchao Su, Xi Zhao
  • Publication number: 20210256220
    Abstract: An autonomous automated intent mining system extracts intents from stored conversations in a text-based chat corpus for use in an AI-driven dialog system. The intent mining system includes an intelligent pre-processor for extracting the conversation data from a computer memory and operating on the conversation data to identify relevant utterances. The system additionally includes a representation processor for operating on the identified relevant utterances to create a numerical representation. The system also includes a clustering processor for generating clusters of utterances and classifying each of the identified relevant utterances into a cluster based on the numerical representation of each utterance. Each generated cluster represents a unique intent for use in the AI-driven dialog system.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 19, 2021
    Inventors: Simarjot KAUR, Sachin MITTAL, Sandya Srivilliputtur MANNARSWAMY
  • Patent number: 11077050
    Abstract: The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: August 3, 2021
    Assignees: Merck Sharp & Dohme Corp., Merck Sharp & Dohme B.V.
    Inventors: Sachin Mittal, Irina Kazakevich, Himanshu Bhattacharjee, Peter Bakker, Luke Schenck, David J. Goldfarb, Amitava Mitra, Donna Carroll, Nazia Khawaja
  • Publication number: 20210141635
    Abstract: Some embodiments may facilitate software development and operations for an enterprise. A communication input port may receive information associated with a software continuous integration/deployment pipeline of the enterprise. An intelligent software agent platform, coupled to the communication input port, may listen for a trigger indication from the software continuous integration/deployment pipeline. Responsive to the trigger indication, the intelligent software agent platform may apply system configuration information and rule layer information to extract software log data and apply a machine learning model to the extracted software log data to generate a pipeline health check analysis report. The pipeline health check analysis report may include, for example, an automatically generated prediction associated with future operation of the software continuous integration/deployment pipeline.
    Type: Application
    Filed: January 21, 2021
    Publication date: May 13, 2021
    Inventors: Renoi Thomas, Satish Venugopal, Sachin Mittal, Sandeep Kumar Yaramchitti
  • Patent number: 10963242
    Abstract: Some embodiments may facilitate software development and operations for an enterprise. A communication input port may receive information associated with a software continuous integration/deployment pipeline of the enterprise. An intelligent software agent platform, coupled to the communication input port, may listen for a trigger indication from the software continuous integration/deployment pipeline. Responsive to the trigger indication, the intelligent software agent platform may apply system configuration and rule layer information to extract software log data and apply a machine learning model to the extracted software log data to generate a pipeline health check analysis report. The pipeline health check analysis report may include, for example, an automatically generated prediction associated with future operation of the software continuous integration/deployment pipeline.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: March 30, 2021
    Assignee: Hartford Fire Insurance Company
    Inventors: Renoi Thomas, Jr., Satish Venugopal, Sachin Mittal, Sandeep Kumar Yaramchitti
  • Publication number: 20200401397
    Abstract: Some embodiments may facilitate software development and operations for an enterprise. A communication input port may receive information associated with a software continuous integration/deployment pipeline of the enterprise. An intelligent software agent platform, coupled to the communication input port, may listen for a trigger indication from the software continuous integration/deployment pipeline. Responsive to the trigger indication, the intelligent software agent platform may apply system configuration and rule layer information to extract software log data and apply a machine learning model to the extracted software log data to generate a pipeline health check analysis report. The pipeline health check analysis report may include, for example, an automatically generated prediction associated with future operation of the software continuous integration/deployment pipeline.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 24, 2020
    Inventors: Renoi Thomas, Satish Venugopal, Sachin Mittal, Sandeep Kumar Yaramchitti
  • Publication number: 20200289406
    Abstract: The instant invention provides pharmaceutical formulations for a long acting injectable drug product comprising a suspension of doravirine for parenteral administration via intramuscular or subcutaneous routes. The drug product can be used for the treatment or prophylaxis of infection by HIV or for the treatment, prophylaxis, or delay in the onset of AIDS (acquired immunodeficiency syndrome) or ARC (AIDS related complex).
    Type: Application
    Filed: March 19, 2018
    Publication date: September 17, 2020
    Applicants: MERCK SHARP & DOHME CORP., MERCK SHARP & DOHME B. V.
    Inventors: Sachin Mittal, Irina Kazakevich, Himanshu Bhattacharjee, Peter Bakker, Luke Schenck, David J. Goldfarb, Amitava Mitra, Donna Carroll, Nazia Khawaja
  • Publication number: 20200276274
    Abstract: Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.
    Type: Application
    Filed: February 26, 2020
    Publication date: September 3, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Himanshu Bhattacharjee, Suzanne M. D'Addio, Sachin Lohani, Sachin Mittal, Sergei Y. Pechenov, Daniel Hong Yin
  • Patent number: 8551942
    Abstract: A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: October 8, 2013
    Assignee: Merck Sharp & Dohme, Corp.
    Inventors: Sachin Mittal, Hossain Jahansouz, Sutthilug Sottivirat
  • Publication number: 20130023462
    Abstract: A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.
    Type: Application
    Filed: September 27, 2012
    Publication date: January 24, 2013
    Inventors: Sachin Mittal, Hossain Jahansouz, Sutthilug Sotthivirat
  • Publication number: 20100216848
    Abstract: A liquid pharmaceutical composition comprising N-[1S,2S]-3-[(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[(5-trifluoromethyl)pyridine-2-yl]oxy}propanamide is disclosed, together with processes of preparing the liquid pharmaceutical composition, preparing a vessel containing the liquid pharmaceutical composition, the use of the composition for treating and preventing diabetes or obesity and a method of treating or preventing diabetes or obesity comprising administration to a patient in need thereof of an effective amount of the liquid pharmaceutical composition.
    Type: Application
    Filed: October 6, 2008
    Publication date: August 26, 2010
    Inventors: Andrey V. Peresypkin, Sachin Mittal
  • Publication number: 20100137197
    Abstract: A lyophilized anti-fungal composition comprises (A) caspofungin, or a pharmaceutically acceptable salt thereof, in an effective amount; (B) one or more non-reducing sugars having a glass transition temperature Tg(s) of at least about 90° C.; and (C) an acetate buffer in an amount effective to provide a pH in a range of from about 5 to about 7; wherein the weight ratio of the one or more non-reducing sugars to caspofungin is in a range of from about 1.1:1 to about 10:1; the composition has a moisture content of about 0.8 wt. % or less; and the composition has a glass transition temperature Tg(c) of at least about 55° C. The lyophilized composition has good storage stability at temperatures up to and including room temperature. The composition can be reconstituted for use in preventing or treating fungal infections.
    Type: Application
    Filed: June 23, 2008
    Publication date: June 3, 2010
    Inventors: Sachin Mittal, Hossain Jahansouz, Suttilug Sotthivirat